Alan William O'Connell

Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland.

PrecisionBiotics Group Ltd. operates as a healthcare company. It focuses on isolation, characterization, clinical evaluation, and formulation of unique bacterial strain and actives for inflammatory and infectious conditions. The company was founded by Barry Kiely in 1999 and is headquartered In Cork, Ireland.

Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom.

Kernel Management Partners Ltd. (Kernel Capital) is a venture capital firm founded in 1999 by Niall Olden. The firm is headquartered in Cork, Ireland.

Biosensia Ltd. develops multiplexing point of care in vitro diagnostics platform. It offers RapiPlex, a point-of-care diagnosis system based on a set of proprietary technologies capable of producing quantitative and qualitative laboratory quality test results. The company was founded by Gareth Redmond and Gabriel Crean in 2009 and is headquartered in Dublin, Ireland.

Diabetica Ltd. develops drugs to treat diabetes. Its primary business is the development of novel therapeutics, diagnostic and other innovative technologies in the areas of type 2 diabetes, obesity and metabolic syndrome. The company was founded in September 2004 by Peter Flatt, Neville McClenaghan and Finbarr O'Harte and is headquartered in Coleraine, the United Kingdom.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.